Stop TB Partnership

Working Groups and Task Forces

The Working Groups of the Partnership provide inputs on critical strategic issues for TB globally, based on which the board takes decisions. One of the strategic goals of the Partnership is to strengthen support for the working groups and to facilitate collaboration between them. The Partnership identifies opportunities and gaps for new partners to engage in Working Groups through ongoing and regular dialogue. There are seven different working groups.

DOTS Expansion Working Group

The DOTS Expansion Working Group (DEWG) represents an inter-institutional arrangement between the World Health Organization (WHO), major financial and technical partners, national TB control programmes (NTPs), the Global Drug Facility (GDF), and community representatives to expand access to TB diagnosis and treatment in line with the Millennium Development Goals and the Stop TB Partnership targets.

Since its inception in 2000, the DEWG has established a core team, a secretariat and five subgroups. Each subgroup focuses on specific elements of DOTS expansion and enhancement including public-private mix (PPM), childhood TB, poverty, and retooling. The working group has been involved in enhancing DOTS activities in countries, preparing national plans to control TB and forging national TB partnerships.

Global Drug-resistant TB Initiative

This working group serves as a multi-institutional, multi-disciplinary platform organizing and coordinating the efforts of stakeholders to assist countries to build capacity for programmatic management of DR-TB in the public and private sector. The aim is to ensure universal access to care and appropriate treatment for all DR-TB patients. The group mobilizes resources and undertake activities to ensure a holistic, quality-assured, patient-centred approach for all DR-TB patients within existing TB care structures as well as through innovative new partnerships in priority countries.

TB/HIV Working Group

The TB/HIV Working Group, set up in 2001, aims to coordinate, monitor, advise, collect and share information around the global response to the HIV associated TB epidemic. The HIV pandemic presents a massive challenge to the global control of TB at all levels. Globally, TB is also the commonest presenting illness among people living with HIV (PLHIV) both before and after receiving antiretroviral therapy. The Working Group developed a core set of policy and program guidance based on the best available evidence to reduce the impact of the TB and HIV epidemics (Interim policy on collaborative TB/HIV activities, 2004 subsequently updated to the WHO Policy on collaborative TB/HIV activities).

Working Group on New TB Diagnostics

The New Diagnostics Working Group (NDWG) focuses on promoting development and adoption of new and modified diagnostic products. The group has contributed significantly to the advances in the field of TB diagnostics. Promising technologies have been screened and a series of new product developments initiated, supported, subjected to field trials and ultimately endorsed by WHO for roll-out in endemic settings.

The group is working on a scientific blueprint for the development of TB diagnostics. This publication is intended to facilitate coordination and collaboration across the diagnostic research and development landscape. It provides a framework to guide all those involved in diagnostic development through the different phases of the development value chain - from the discovery of new techniques and tools through to their delivery and implementation in high-endemic countries.

Working Group on New TB Drugs

The Working Group on New Drugs (WGND) has a mandate to accelerate the development of effective and affordable new therapies for TB. It acts as a forum to facilitate global collaborations and joint projects for the development of new TB drugs. To eradicate TB in the 21st century, a continued multi-year worldwide commitment, research and vigilance is important to ensure a consistent pipeline of new antimicrobials. With its diverse membership, including representatives of public and private sector, academic laboratories, the industry as well as regulators, representatives of affected communities and those in a position to provide funding and support, the working group remains a unique mechanism for ensuring a consistent pipeline of drug candidates.

Working Group on New TB Vaccines

The purpose of the Working Group on New TB Vaccines is to facilitate the development of new, more effective TB vaccine by promoting collaboration and coordination amongst multiple stakeholders. The Working Group serves as the mechanism of exchange and dialogue between the Stop TB Partnership and the research community, provides a forum to discuss challenges to TB vaccine development and identify solutions, and to build consensus on key issues and questions related to TB vaccine research and development.

Global Laboratory Initiative

The Global Laboratory Initiative (GLI) is a network of international partners dedicated to accelerating and expanding access to quality assured laboratory services in response to the diagnostic challenges of TB, notably HIV-associated and drug-resistant TB. The GLI provides a focus for TB within the framework of a multi-faceted yet integrated approach to laboratory capacity strengthening.

TB and Human Rights Task Force

The aim of the TB and Human Rights Task Force is to protect and promote human rights, in pursuit of universal access to TB prevention, diagnosis and treatment. The purpose of the Task Force is to develop a joint WHO, UNAIDS and Stop TB Partnership policy framework for a rights-based approach to Stop TB so as to advance health, development and effective TB prevention, diagnosis and treatment. The Task Force is composed of major stakeholders constituencies from affected communities and risk groups, UN agencies, human rights and civil society organizations, health and human rights experts and development partners.